WASHINGTON (Reuters) - The Obama administration asked a federal judge on Tuesday to lift an injunction halting human embryonic stem cell research, saying it would irreparably harm research and cost more than 1,300 jobs.

LONDON (Reuters) - Tens of millions of people in low and middle income countries would be pushed below the poverty line by buying common but vital medicines which are already unaffordable to hundreds of millions more, a study has found.

NEW YORK (Reuters Health) - Some thirty years after authorities doled out the last dose of smallpox vaccine, the world faces another multiplying menace: monkeypox.

CHICAGO (Reuters) - Women with mutations in the well-known BRCA1 or BRCA2 genes who have their breasts and ovaries removed are much more likely to survive than women who do not get preventive surgery, U.S. researchers said on Tuesday.

NEW YORK (Reuters Health) - Full-term babies born a bit on the early or late side are at higher risk of cerebral palsy, according to a new study in nearly 1.7 million Norwegian children.

CHICAGO (Reuters) - Two Iowa egg farms linked to a salmonella outbreak that has sickened thousands failed to follow their own safety plans, allowing rodents and other animals into poultry houses, U.S. Food and Drug Administration inspectors found.

NEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.

WASHINGTON (Reuters) - U.S. health officials are set to rule on whether a faster-growing, genetically engineered fish is safe to eat in a decision that could deliver the first altered animal food to consumers’ dinner plates.

CHICAGO (Reuters) - A Purdue University food scientist using infrared spectroscopy took only an hour to find harmful E. coli bacteria in ground beef, a discovery that could cut days off investigations of outbreaks, the university said in a statement on Monday.

PARIS/BOSTON (Reuters) - Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially hostile takeover battle.